Nasdaq GlobeNewswire

SD-WAN Market Leader Aryaka Unveils PASSPORT: Multi-Layered Security Platform and Ecosystem, Partners with Palo Alto Networks, Zscaler, and Radware

Del

First Integrated Platform for Best-of-Breed Application Performance and Multi-Layered Security for Global Enterprises

 

SAN MATEO, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, today unveiled PASSPORT, its multi-layered security platform and ecosystem, providing global enterprises with best-in-class application performance and security.

"In today's cloud-centric world, global organizations are looking to SD-WAN to deliver solutions that offer reliable global connectivity, fast and consistent application performance anywhere in the world, and enhanced network visibility in an environment that assures the highest level of enterprise-grade security," said Gary Sevounts, Chief Marketing Officer at Aryaka. "Working closely with industry leaders like Palo Alto Networks, Zscaler, and Radware, Aryaka delivers a platform with unified, best-of-breed global SD-WAN and security solutions that are affordable and accessible to all global enterprises."

Components of Aryaka's PASSPORT include:

  • Aryaka's global private network provides enterprises with an essential level of security, ensuring that business-critical application traffic is not exposed to the public Internet and does not have entry points that can be exploited by threat actors.  Each company's traffic traverses through dedicated, not shared, layer 2 links with enterprise-grade end-to-end encryption.
     
  • Aryaka's network is fortified with industrial-grade security measures, including DDoS attack prevention using Radware's Hybrid Cloud Attack Mitigation.
     
  • Aryaka's edge devices provide built-in advanced security measures such as firewalls and intrusion prevention, as well as integration with Next-Generation firewalls from Palo Alto Networks. 
     
  • Aryaka provides a layer of advanced cloud security for non-critical traffic that traverses over the Internet via partnerships with Palo Alto Networks GlobalProtectTM Cloud Services and Zscaler Cloud Security.
     
  • Aryaka provides a combination of industry-leading accelerated direct connectivity to all SaaS and cloud platforms along with additional integrated security from Palo Alto Networks for virtual firewalls hosted in services such as AWS and Microsoft Azure.

Aryaka's Security Ecosystem:

Along with developing its own advanced security controls and layers, Aryaka is providing additional security through three key partnerships with best-in-class enterprise security vendors:

  • Palo Alto Networks: As a key component of the integration, Aryaka and Palo Alto Networks provide enterprises with industrial-grade security, including on-premises, cloud-based, and many other cloud service models.
  • Radware: The technology deployment implements best-in-class DDoS (Distributed Denial of Service) attack detection and mitigation through Aryaka's private network for their global enterprise customers.
  • Zscaler: All non-critical Internet traffic can be forwarded over to the Zscaler cloud to provide advanced security services such as threat protection, data protection, and access control capabilities.

"The cloud has caused enterprises to rethink traditional approaches to network and security solutions in a world where the data center is no longer the defacto destination," said Punit Minocha, Zscaler SVP of Business and Corporate Development. "We are proud to be working with Aryaka on a solution that supports enterprise-class connectivity and provides the performance, security, and agility needed in today's cloud-first world."

By supporting a variety of different use cases, Aryaka, Zscaler, Radware, and Palo Alto Networks allow organizations to benefit from cloud-native private connectivity, application acceleration, SD-WAN, and security solutions without adding network complexity and costs.

Deployed by more than 800 global enterprises, Aryaka is the leading global SD-WAN provider and has the fastest growing SD-WAN solution in the market today, delivering enhanced performance for cloud and on-premises applications worldwide. Aryaka's global SD-WAN has quickly become the only viable MPLS replacement solution for global enterprises requiring alternatives to legacy WAN infrastructures for mission-critical application delivery.

For information about Aryaka, visit www.aryaka.com.

About Aryaka
Aryaka is transforming how global enterprises connect sites and users worldwide, and use mission-critical applications to support modern business execution demands. Aryaka's Global SD-WAN combines a purpose-built private network, SD-WAN, optimization and acceleration techniques, connectivity to cloud platforms, and network visibility in a single solution that is delivered as a service.

To learn more, visit www.aryaka.com. Follow us on TwitterFacebookYouTube and LinkedIn.

Aryaka Media Contact
Shehzad Karkhanawala
Director of Marketing
Aryaka
408-273-8420
pr@aryaka.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aryaka via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Taconic Biosciences Launches New Inflammatory Bowel Disease Models19.4.2018 14:00Pressemelding

RENSSELAER, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, announces the launch of several new inflammatory bowel disease (IBD) animal models. As a fully-licensed provider of CRISPR/Cas9 gene editing technology, Taconic scientists knocked out the mouse Il10 gene to generate a spontaneous colitis mouse models. The new knockout models were created on Taconic's B6 (C57BL/6NTac) and BALB/c (BALB/cAnNTac) backgrounds, and are available at both the Excluded Flora (EF) and Germ Free (GF) health standards. Beyond the scientific benefits, Taconic is also making them easy to access by offering these models to commercial, contract research organization (CRO), and academic institutions under a simple label license. This represents a departure from the license requirements for Il10 knockouts from other animal model providers. "In order for animal models to drive drug discovery they need to be both

Cisco ACI Is Data Center Solution of Choice for Service Providers Worldwide19.4.2018 14:00Pressemelding

Service providers deliver new cloud services more quickly and offer superior customer experience with the help of Cisco Application Centric Infrastructure SAN JOSE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Providing secure, differentiated and rapidly delivered cloud services to customers is a crucial requirement for today's service providers. To meet cloud infrastructure demands, global service providers are increasingly turning to the Cisco® Application Centric Infrastructure (Cisco ACI(TM)) , the industry-leading software-defined networking (SDN) solution. Cisco ACI reduces operational costs with an automated, policy-based programmable architecture, while improving scalability and security. In addition, new Cisco ACI multi-site management capability helps service providers to connect and manage multiple geographically distributed Cisco ACI fabrics and to move and manage workloads with a single pane of glass. Cisco ACI is being deployed worldwide by service providers such as NTT Com

FinancialForce Extends Professional Services Automation Leadership With its Spring 2018 Release19.4.2018 14:00Pressemelding

New features empower services organizations to run their businesses with greater predictability, assign best-fit resources at scale, and forecast projects with 360-degree insight. SAN FRANCISCO, April 19, 2018 (GLOBE NEWSWIRE) -- FinancialForce, the number one customer-centric ERP cloud vendor built on the Salesforce Platform, announced the availability of its latest version of Professional Services Automation, the highest customer-rated PSA solution for enterprise organizations. The Spring 2018 Release of PSA brings new functional capabilities to accelerate project staffing speed and accuracy; unify people and project data; enable better forecasting decisions; and enhance the overall user experience using the Salesforce Lightning framework. Fast, Accurate Resource Mapping With the Spring 2018 Release of PSA, project and resource managers can identify and assign best-fit resources with greater speed and accuracy. Through advanced skills filtering and search capabilities, including part

SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00Pressemelding

SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult

SEMAFO: Construction of Boungou Mine 91% Complete19.4.2018 13:00Pressemelding

Commissioning Advancing to Plan MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) announced that construction of the Boungou Mine in Burkina Faso is 91% complete, and commissioning activities are advancing well with 10% already completed at the end of March. Since launch of commissioning at the end of February, the crushing circuit equipment and water services have been tested and commissioned. The reclaim and grinding circuits, reagent and oxygen plants are also undergoing testing. Wet commissioning began at the end of March with the Corporation pumping water from the water storage facility to the raw water tanks for the processing plant. We are still in line to achieve our first gold pour early in the third quarter of 2018. As at March 31, 2018, the following milestones had been reached: Development on budget with US$194 million of the US$231 million capital expenditure incurred Construction of the mine 91% complete Completion of 98% of structural steel and

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 201819.4.2018 13:00Pressemelding

Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments. To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeut

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom